ArticleBlood2018
A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens.
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 59 citations in OpenAlex.
- Article
- Peptide-MHC-targeted engineered virus-like particles enable selective priming and gene editing of tumor-specific T cells.Cell reports · 2026Article
- The TCXpress lane to T-cell receptor-engineered T cells.Blood advances · 2026Article
- Article
- Identification of antigen-specific functional CD8iScience · 2025Article
- A functionally validated TCR-pMHC database for TCR specificity model development.bioRxiv : the preprint server for biology · 2025Article
- Rapid parallel reconstruction and specificity screening of hundreds of T cell receptors.Nature protocols · 2025Review
- Discovery of tumor-reactive T cell receptors by massively parallel library synthesis and screening.Nature biotechnology · 2025Article
- Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.Nature communications · 2025Article
- Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies.Theranostics · 2025Review
- Diminished Diversities and Clonally Expanded Sequences of T-Cell Receptors in Patients with Chronic Spontaneous Urticaria.ImmunoTargets and therapy · 2024Article
- Cell activation-based screening of natively paired human T cell receptor repertoires.Scientific reports · 2023Article
- Single-Cell Analysis in Immuno-Oncology.International journal of molecular sciences · 2023Review
- Dynamics and specificities of T cells in cancer immunotherapy.Nature reviews. Cancer · 2023Review
- TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.Cell reports methods · 2023Article
- Tumor neoantigens: Novel strategies for application of cancer immunotherapy.Oncology research · 2023Review
- Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
- Rapid cloning of antigen-specific T-cell receptors by leveraging the cis activation of T cells.Nature biomedical engineering · 2022Article
- Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners.JCI insight · 2022Article
- Landscape of helper and regulatory antitumour CD4Nature · 2022Article
Corrections and comments
- Commented on by
Authors and funding
26 authors at 6 institutions in 2 countries.
Funding
Abstract
Recent studies have highlighted the promise of targeting tumor neoantigens to generate potent antitumor immune responses and provide strong motivation for improving our understanding of antigen-T-cell receptor (TCR) interactions. Advances in single-cell sequencing technologies have opened the door for detailed investigation of the TCR repertoire, providing paired information from TCRα and TCRβ, which together determine specificity. However, a need remains for efficient methods to assess the specificity of discovered TCRs. We developed a streamlined approach for matching TCR sequences with cognate antigen through on-demand cloning and expression of TCRs and screening against candidate antigens. Here, we first demonstrate the system's capacity to identify viral-antigen-specific TCRs and compare the functional avidity of TCRs specific for a given antigen target. We then apply this system to identify neoantigen-specific TCR sequences from patients with melanoma treated with personalized neoantigen vaccines and characterize functional avidity of neoantigen-specific TCRs. Furthermore, we use a neoantigen-prediction pipeline to show that an insertion-deletion mutation in a putative chronic lymphocytic leukemia (CLL) driver gives rise to an immunogenic neoantigen mut-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.